Efficacy analyses
tumors
SECONDARY, TUMORS
Among the 57 patients, MSS status was known for 51 patients; three had MSI status; and 48 had MSS status. Only the 48 patients with MSS tumors were included in the eligible population for efficacy analyses, per protocol. Median follow-up was 36 months (2.5–33.9). The primary objective of phase 2 was met, with 3-month PFS of 90.7% (95% confidence interval (CI): 79.2–96%). Six-month, 12-month and 24-month PFS was, respectively, 60.4% (95% CI: 45.2–72.6%), 26.9% (95% CI: 15.3–39.9%) and 6.7% (95% CI: 1.8–16.5 %). Regarding secondary objectives, median PFS was 8.2 months (95% CI: 5.9–8.6) (Fig. 